PEPCLUB

.me
Peptide Intelligence
Start freeLog in
PEPCLUB.me
Log inStart free
Body CompositionWeight ManagementMetabolic HealthArticlePremium

HGH Fragment 176-191

2mg Vial
5mg Vial
10mg Vial
2 September 2026Updated 2 September 2026
OverviewResearch0MechanismProtocolsSafety
Discussions
This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for HGH Fragment 176-191.

Create free accountMember login
Full range of benefits for HGH Fragment 176-191

Promotes lipolysis and fatty acid mobilization in adipose tissue

May reduce fat mass and adipocyte size (seen in preclinical studies)

May help preserve lean body mass during weight loss

Minimal impact on blood glucose and insulin vs full-length HGH

Increases fatty acid oxidation and metabolic rate in animal models

Targets visceral and subcutaneous fat in preclinical research

Lower mitogenic/IGF-1 activity than native HGH

Short peptide fragment with targeted, non-growth-promoting actions

Studied as adjunct to lifestyle interventions for body composition

Generally well tolerated in early clinical and preclinical studies

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 13 known interactions
Synergistic(3)Compatible(3)Monitor(3)Avoid(4)

Not recommended for concurrent use

Recombinant human growth hormone (rhGH)

Combining with systemic rhGH may increase overall GH‑axis exposure and risk of GH‑related adverse effects, so clinicians should carefully evaluate necessity and cumulative dosing.

Systemic corticosteroids (e.g., prednisone)

Glucocorticoids counteract lipolysis and worsen metabolic parameters, potentially opposing intended effects and increasing metabolic risk when used concurrently.

Oral estrogen therapy

Estrogen can modify GH axis dynamics and binding proteins, which may alter peptide efficacy and risk profile, warranting individualised assessment before co‑administration.

Warfarin (vitamin K antagonist anticoagulant)

Although direct interaction is unlikely, metabolic or hepatic changes from co‑therapies can alter warfarin metabolism and INR, so anticoagulation status should be reviewed and monitored if combined.

All interaction categories

Synergistic (3)

  • Ipamorelin: A ghrelin receptor agonist and growth hormone secretagogue that can increase endogenous GH pulses and may potentially augment the lipolytic/fat‑mobilising effects attributed to HGH Fragment 176-191.
  • CJC-1295 (GHRH analog): A GHRH analog that raises endogenous GH secretion and, when used with lipolytic peptides, may have additive effects on fat metabolism while requiring assessment of overall GH exposure.
  • L-Carnitine: A fatty acid transport cofactor commonly used to support fatty acid oxidation that can complement the intended fat‑metabolism outcomes of HGH Fragment 176-191 without known direct pharmacologic antagonism.

Compatible (3)

  • Metformin: An insulin-sensitising agent with a neutral co-administration profile that does not have known direct pharmacodynamic conflict with HGH Fragment 176-191 and is frequently used concurrently in metabolic management.
  • Atorvastatin (statin class): Lipid‑lowering HMG‑CoA reductase inhibitors have no well‑documented direct interaction with HGH Fragment 176-191 and are generally compatible when cardiovascular risk management is required.
  • Omega-3 fatty acids: Nutraceuticals that support lipid metabolism and inflammation and are considered compatible with no expected direct pharmacologic interaction with the peptide.

Monitor (3)

  • Insulin: Because changes in lipolysis, body composition or insulin sensitivity can occur with metabolic therapies, blood glucose and insulin requirements should be monitored and adjusted as needed when co-administered.
  • Sulfonylureas: Oral hypoglycaemic agents can increase hypoglycaemia risk if metabolic state changes; glucose levels and dosing should be monitored when starting or stopping the peptide.
  • Levothyroxine: Thyroid hormone alters basal metabolic rate and lipid handling, so thyroid function tests and clinical status should be monitored as co‑therapy may change levothyroxine dose requirements.

Avoid (4)

  • Recombinant human growth hormone (rhGH): Combining with systemic rhGH may increase overall GH‑axis exposure and risk of GH‑related adverse effects, so clinicians should carefully evaluate necessity and cumulative dosing.
  • Systemic corticosteroids (e.g., prednisone): Glucocorticoids counteract lipolysis and worsen metabolic parameters, potentially opposing intended effects and increasing metabolic risk when used concurrently.
  • Oral estrogen therapy: Estrogen can modify GH axis dynamics and binding proteins, which may alter peptide efficacy and risk profile, warranting individualised assessment before co‑administration.
  • Warfarin (vitamin K antagonist anticoagulant): Although direct interaction is unlikely, metabolic or hepatic changes from co‑therapies can alter warfarin metabolism and INR, so anticoagulation status should be reviewed and monitored if combined.